SWK (NASDAQ:SWKH) Stock Price Up 0.4% – Here’s Why

by · The Cerbat Gem

SWK Holdings Co. (NASDAQ:SWKH – Get Free Report) shares rose 0.4% during mid-day trading on Wednesday . The stock traded as high as $16.25 and last traded at $15.85. Approximately 3,815 shares changed hands during trading, a decline of 64% from the average daily volume of 10,682 shares. The stock had previously closed at $15.79.

SWK Stock Performance

The stock has a fifty day moving average price of $16.60 and a 200 day moving average price of $16.93. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.11. The firm has a market cap of $192.74 million, a price-to-earnings ratio of 17.04 and a beta of 0.36.

Hedge Funds Weigh In On SWK

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of SWK by 75.5% during the 1st quarter. Vanguard Group Inc. now owns 397,273 shares of the company’s stock worth $6,920,000 after purchasing an additional 170,957 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of SWK during the third quarter worth approximately $589,000. SkyView Investment Advisors LLC boosted its position in shares of SWK by 7.7% in the second quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock valued at $529,000 after acquiring an additional 2,234 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of SWK by 85.7% in the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock worth $511,000 after acquiring an additional 13,892 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in SWK during the second quarter worth $172,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

SWK Company Profile

(Get Free Report)

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.

Featured Articles